Institute of Neurobiology of Biomedical Research Center, Slovak Academy of Sciences, Košice, Slovak Republic. Faculty of Medicine, Clinic of Trauma Surgery, P. J. Šafárik University, Košice, Slovak Republic.
Physiol Res. 2021 Nov 29;70(5):661-670. doi: 10.33549/physiolres.934644. Epub 2021 Sep 10.
Application of knowledge about ischemic tolerance to clinic requires the solid understanding of mechanism of creation of this phenomenon. This review summarizes research that has been carried out in many laboratories over a long period of time, but the main focus will be on own experimental research. The main emphasis is devoted to the possibility of preparing full tolerance in the donor's body and its transfer to the patient in the form of activated blood plasma. Such plasma could be administered as soon as the patient is transported to the hospital and would take effect immediately after administration to the patient's bloodstream. One chapter is also devoted to anticonditioning, i.e. the possibility of preventing the activation of tolerance. Anticonditioning could be used to treat oncologic patients. We expect that this method could increase effectiveness of cancer treatment. Cross-tolerance with a wide range of diverse stressors gives us the courage to assume that activated plasma can significantly help with a wide range of pathological events.
将关于缺血耐受的知识应用于临床需要对该现象产生机制有扎实的理解。这篇综述总结了许多实验室在很长一段时间内进行的研究,但主要重点将放在自身的实验研究上。主要重点放在供体体内完全耐受的可能性及其以激活的血浆形式转移到患者身上。这种血浆可以在患者被送往医院时给予,并在给予患者血流后立即生效。还有一章专门介绍抗条件作用,即预防耐受激活的可能性。抗条件作用可用于治疗肿瘤患者。我们期望这种方法可以提高癌症治疗的效果。与广泛的不同应激源的交叉耐受使我们有信心假设激活的血浆可以显著帮助广泛的病理事件。